Meeting
2019 ASCO Annual Meeting
A phase I study of the oral administration of irinotecan in combination with the potent P-glycoprotein (P-gp) inhibitor HM30181A.
Authors
Antonio Jimeno
University of Colorado, Aurora, CO
Antonio Jimeno , Mateusz Opyrchal , Jennifer Robinson Diamond , Christos Fountzilas , Bradley Corr , Ildiko Bezi , Hui Wang , Rudolf Kwan , Jay Zhi , David Cutler , Patrick McKay Boland
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Chemotherapy and Antibody-Drug Conjugates
Clinical Trial Registration Number
NTC02250157
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3032)
DOI
10.1200/JCO.2019.37.15_suppl.3032
Abstract #
3032
Poster Bd #
24
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk
Poster
2019 ASCO Annual Meeting
Phase I study of DFP-11207, a novel oral 5-FU with enhanced PK and improved tolerability, in patients with solid tumors.
First Author: Jaffer A. Ajani
Poster
2017 ASCO Annual Meeting
Phase I study combining the aurora kinase A (AURKA) inhibitor alisertib (Ali) with mFOLFOX in gastrointestinal (GI) cancer.
First Author: Laura Williams Goff
Poster
2017 ASCO Annual Meeting
Phase 1 results of PTC596, a novel small molecule targeting cancer stem cells (CSCs) by reducing levels of BMI1 protein.
First Author: Jeffrey R. Infante